to 10, 2026
Human Phage Therapy
This mini-symposium on human phage therapy will bring together researchers, clinicians, and other stakeholders in the field to take stock of recent advances, clinical applications, and the
challenges associated with the development of this therapeutic approach. Presentations will cover, among other topics, phage collections, the production of therapeutic phages,
clinical experience, as well as regulatory aspects and the prospects for the development of phage therapy in Quebec, Canada, and internationally.
Tuesday, November 10, 2026, 1:30 p.m. to 5:00 p.m.
Charles-Eugène Marchand Pavilion, Hydro-Québec Room (1210)
Laval University Campus
1:30 PM – 2:15 PM Prof. Sylvain Moineau, PhD, Department of Biochemistry, Microbiology, and Bioinformatics, Faculty of Science and Engineering, Laval University, Quebec City
• Laval University’s phage collection: a unique collection supporting research and phage therapy
2:15 PM – 3:00 PM Nancy Tawil, PhD, President, Qeen Biotechnologies Inc., Gatineau
• Phage therapy in Canada: Qeen, from GMP manufacturing to the patient’s bedside
3:00 p.m. – 3:15 p.m. Break
3:15 p.m. – 4:00 p.m. Félix-Antoine Garneau-Picard, MD, Microbiologist and Infectious Disease Specialist, Laval University and CHU de Québec (Hôpital Enfants-Jésus), Québec
• Clinical phage therapy: evidence, regulatory frameworks, and the British experience
4:00 PM – 5:00 PM Tristan Ferry, MD, PhD, Claude-Bernard Lyon 1 University, Hospices Civils de Lyon,
Department of Infectious and Tropical Diseases, Lyon, France
• From compassionate use to clinical trials: nearly ten years of phage therapy development in France
The presentations will also be available on Zoom via the following link:
https://ulaval.zoom.us/j/8156465253?pwd=TkRaUFhtQVNxd0s1djdCdkIzaXcrdz09
Participation in this mini-symposium is free, but if you plan to attend in person, please let us know at Collection.Phages@bcm.ulaval.ca